Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.

Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O

Diabetes care5 Mar 2020Cited by 138 (Europe PMC)

PMID32139381PMCIDPMC7171937DOI10.2337/dc19-1745PepBankPUB-32139381

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg reduced weight more than placebo at 56 weeks.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg led to more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseMean weight change at week 56
Study
n = 396
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Measurements
Mean weight change
−5.8%
liraglutide 3.0 mg
Mean weight change
−1.5%
placebo
Source sentences
Summary
At 56 weeks, mean weight change was -5.8% for liraglutide 3.0 mg versus -1.5% with placebo (estimated treatment difference -4.3% [95% CI -5.5; -3.2]; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938101
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, more people on liraglutide 3.0 mg than on placebo lost at least 5% of body weight.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, more people lost at least 5% of weight with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of 5% or more
Study
n = 396
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Measurements
Proportion with weight loss >=5%
51.8%
liraglutide 3.0 mg
Proportion with weight loss >=5%
24%
placebo
Source sentences
Summary
With liraglutide 3.0 mg, 51.8% of individuals achieved ≥5% weight loss versus 24.0% with placebo (odds ratio 3.41 [95% CI 2.19; 5.31]; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938102
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg reduced mean HbA1c more than placebo.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction
Study
n = 396
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide 3.0 mg was associated with significantly greater reductions in mean HbA_1c and mean daytime glucose values and less need for insulin versus placebo, despite a treat-to-glycemic-target protocol.
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938103
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg reduced mean daytime glucose more than placebo.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg lowered daytime blood sugar more than placebo.
Peptide
Liraglutide
Outcome
DecreaseMean daytime glucose
Study
n = 396
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide 3.0 mg was associated with significantly greater reductions in mean HbA_1c and mean daytime glucose values and less need for insulin versus placebo, despite a treat-to-glycemic-target protocol.
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938104
05HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg was associated with less need for insulin than placebo.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, people on liraglutide 3.0 mg needed less insulin than people on placebo.
Peptide
Liraglutide
Outcome
DecreaseInsulin need
Study
n = 396
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide 3.0 mg was associated with significantly greater reductions in mean HbA_1c and mean daytime glucose values and less need for insulin versus placebo, despite a treat-to-glycemic-target protocol.
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938105
06HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, hypoglycemic events were more frequent with placebo than with liraglutide 3.0 mg.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, low blood sugar events were more common with placebo than with liraglutide 3.0 mg.
Peptide
Liraglutide
Outcome
DecreaseHypoglycemic events
Study
n = 396
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
More hypoglycemic events were observed with placebo than liraglutide 3.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938106
07HumanRandomized controlled trialSafety outcome
In adults with overweight or obesity and insulin-treated type 2 diabetes, no new safety or tolerability issues were observed with liraglutide 3.0 mg.
In plain wordsIn adults with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg showed no new safety or tolerability issues.
Peptide
Liraglutide
Outcome
No significant changeOverall safety and tolerability
Study
n = 396
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
No new safety or tolerability issues were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
Summary · context
Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT).
Report a problemFND-3213938107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02963922

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Novo Nordisk A/Sn = 3966 Feb 2017 to 25 Sept 2018

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 30 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.